GlassScriptPhysician profile
Mary K Odowd
NPI 1235214214
$3,575.80
in general payments reported to CMS, 2019-2025
33 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $766 · 2021: $1,038 · 2022: $416 · 2023: $473 · 2024: $255 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $438.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $415.07 | 2019-2024 | |
| Amarin Pharma, INC. | $378.74 | 2019-2022 | |
| Lilly USA, LLC | $364.30 | 2019-2025 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $250.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $222.60 | 2019-2024 | Farxiga, Airsupra |
| Ucb, INC. | $176.04 | 2020-2021 | |
| Eisai INC. | $144.12 | 2020-2021 | |
| Astellas Pharma US INC | $136.90 | 2021-2024 | Veozah |
| Merck Sharp & Dohme LLC | $120.04 | 2022-2023 | Belsomra, Verquvo, Januvia |
| Amgen INC. | $116.33 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $106.77 | 2022-2023 | Rexulti |
| Pfizer INC. | $72.63 | 2021-2024 | |
| Avanir Pharmaceuticals, INC. | $62.79 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $59.33 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $54.00 | 2023 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.62 | 2021 | |
| Exact Sciences Corporation | $45.39 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $42.97 | 2022 | |
| Vanda Pharmaceuticals INC. | $35.98 | 2020-2021 | |
| Abbvie INC. | $35.61 | 2021 | |
| Abbott Laboratories | $35.45 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $32.27 | 2020 | |
| Greenwich Biosciences, INC. | $31.69 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.80 | 2021 | |
| Glaxosmithkline, LLC. | $21.21 | 2025 | Shingrix, Arexvy |
| Acadia Pharmaceuticals INC | $20.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.08 | 2025 | Zoryve |
| Optos, INC. | $15.92 | 2021 | |
| Sanofi Pasteur INC. | $15.36 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.67 | 2024 | Quviviq |
| Neurocrine Biosciences, INC. | $12.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Odowd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.